Professor, Obstetrics and Gynecology, Eastern Virginia Medical School
Obstetrics & Gynecology
Dr. David F. Archer, MD
|
|
Give Review
David Archer works in the field of Obstetrics & Gynecology. He went to medical school at University of Louisville School of Medicine. University of Louisville School of Medicine is ranked 83 in research and 0 in primary care medicine He has 1 awards "Fellow (FACOG)". David Archer is a published physician. He published 94 publications, including: 'Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinar...'
Publications
- Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinar...
- Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
- Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability.
- Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
- Contraceptive efficacy, safety, fit, and acceptability of a single-size diaphragm developed with end-user input.
- Recent advances help understand and improve the safety of menopausal therapies.
- New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
- Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension.
- Treatment of Pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
- Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
- Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
- A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women.
- Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.
- Commentary on "menopausal hormone treatment in postmenopausal women: risks and benefits".
- Safety and tolerability of a new low-dose contraceptive patch in obese and non-obese women.
- Dehydroepiandrosterone Intra Vaginal Administration for the Management of Postmenopausal Vulvovaginal Atrophy.
- Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.
- Endometrial safety of ospemifene and the ability of transvaginal ultrasonography to detect small changes in endometrial thickness.
- Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
- Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
- Differential effects of menopausal therapies on the endometrium.
- Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation.
- Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations.
- Soil Diversity and Hydration as Observed by ChemCam at Gale Crater, Mars.
- Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive.
- A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postm...
- Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
- Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey.
- A Randomized Trial Assessing Vaginal Mucosal Safety After 14 Days of Use of Cellulose Sulfate, the Universal HEC Placebo, or Nonoxynol-9 Gel.
- Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.
- The importance of pharmacokinetic studies in drug development.
- Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
- Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgest...
- Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
- Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with Menopause.
- Ethinyl estradiol and 17?-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.
- TSPY4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and contraception studies.
- Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics.
- Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
- Postmenopausal skin and estrogen.
- Vascular dysfunction as a cause of endometrial bleeding.
- Estrogen and progestogen effect on venous thromboembolism in menopausal women.
- Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
- Delivery of therapeutic agents to the target tissue.
- Tailoring combination oral contraceptives to the individual woman.
- Endometrial bleeding in postmenopausal women: with and without hormone therapy.
- The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
- A simple inexpensive screening test for endometrial abnormalities in aSymptomatic women using tamoxifen.
- Levonorgestrel effects on serum androgens, sex hormone-binding globulin levels, hair shaft diameter, and sexual function.
- Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
- Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for Osteoporosis.
- Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausa...
- Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
- Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
- Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant.
- Desvenlafaxine for the treatment of vasomotor symptoms associated with Menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
- A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with Menopause.
- Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells.
- Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
- Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant u...
- Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations.
- Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
- Drospirenone, a progestin with added value for hypertensive postmenopausal women.
- Endometrial effects of tibolone.
- Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data.
- Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
- Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
- Progesterone receptor modulator for emergency contraception: a randomized controlled trial.
- Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives.
- Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.
- FemCap with removal strap: ease of removal, safety and acceptability.
- Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
- Progestogens: effects on clinical and biochemical parameters in postmenopausal women.
- Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
- Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.
- Lower doses of oral estrogen and progestogens as treatment for postmenopausal women.
- Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone.
- A comparison of techniques to assess cervicovaginal irritation and evaluation of the variability between two observers.
- A phase I comparative postcoital testing study of three concentrations of C31G.
- Neoplasia of the female reproductive tract: effects of hormone therapy.
- Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells.
- The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.
- Role of the nonhuman primate for research related to women's health.
- Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells.
- Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cells.
- Hormone therapy and endometrial angiogenesis.
- Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
- Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells.
- Low-dose hormone therapy for postmenopausal women.
- Oral contraceptive efficacy and antibiotic interaction: a myth debunked.
- Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.
- CONTRACEPTION FOR THE 21st CENTURY.
- Development of a Composite Measure of Product Adherence, Protocol Compliance, and Semen Exposure Using DNA and Protein Biomarkers for Topical HIV Prevention Studies.
Schools
University Of Louisville
Louisville Genl Hospital
University Of Pennsylvania
Swedish Med Rsch Council
Procedures Preformed
- Gynecologic Cancer Screening
Conditions Treated
- Carcinoma in Situ
- Chronic Pelvic Pain
- Hyperlipidemia
- Menstrual Disorders (incl. Dysmenorrhea)
- View All
Doctors Specialties
- Obstetrics
- Gynecology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Tier Hosp HealthKeepers DirectAccess VA
- HealthKeepers HMO
- KeyCare PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Southern Health PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Fellow (FACOG)
Education
-
University of Louisville School of Medicine
Drug Facts
| NPI NUMBER | 1558331330 | |
| NPPES Provider LastName | ARCHER | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 235071627 | |
| NPPES Provider State | VA | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 29.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558331330 |
| Last Name Of The Provider | ARCHER |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Raymond C. Lackore, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George M. Kemp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian M. Perez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary A. Burns, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisbet M. Hanson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charysse M. Johnston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monique S. Crabb, MD
This Doctor is OpenDoctor Recommended.
|